Psychedelic Stocks – A New Booming Industry

If any buyers may feel that they were left out of the early boom for a marijuana stock.  Don't worry; there's still plenty of space for the weed industry to expand. However, if you're looking to get into a booming new industry, you may want to look into psychedelic stocks as this may be the next big thing.

This day, psychedelic stocks trade as biotechnology firms. Valuations have received increasing attention due to exciting researches in this field. They, like biotech firms, often announce no revenues and are a highly unpredictable category

The awareness about mental health problems is increasing – so are the numbers of people suffering from them. Despite their pessimism, these conditions serve as catalysts for psychedelic stocks.

Psychedelic stocks in 2021

In the latter half of 2019, regulatory support and promising research results propelled these stocks to new heights. Bright Minds Bio, for example, is a Canadian pharma company focused on psychedelic therapy. Last year, their share soared by 410 percent.

Furthermore, in 2019, the FDA in the United States provided a ray of hope for the industry. It stated that the psychedelic Psilocybin may be a game-changing treatment for depression and mental illnesses.

Promising future opportunities

As per the studies, by 2027, the psychedelic market is estimated to be worth $7 billion. From its current size, that's a compounded annual growth rate of more than 15 percent. Given the global rise in depression and mental illness cases, the growth opportunity is high.

Regulators recently expressed their support for the use of Psilocybin, which increased market interest even further. Psilocybin was approved for medicinal use by Health Canada in November of last year for patients with extreme depression.

Psychedelics have been designated as a breakthrough treatment for acute depression by the FDA.

The state of Oregon has approved a regulatory basis for the use of psilocybin for medicinal purposes. Making history becoming the first state to do so.

Bottom line

The market of psychedelic drugs is just getting started. It would be made possible by the rules and studies that surround it. The COVID-19 pandemic has exacerbated mental wellbeing issues and could serve as a driving force for the sector.

Psychedelics are mostly used for medicinal uses, though commercial use seems to be very limited at this time. As a result, assume a fast turnaround.